Search Results - David A. Lipson

Refine Results
  1. 1
    The complex relationship between microbial growth rate and yield and its implications for ecosystem processes

    The complex relationship between microbial growth rate and yield and its implications for ecosystem processes by David A Lipson

    Published 2015-06-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Realização de broncofibroscopia(BFC) na atelectasia numa unidade de cuidados intensivos(UCI): um caso clínico e revisão da literatura

    Realização de broncofibroscopia(BFC) na atelectasia numa unidade de cuidados intensivos(UCI): um caso clínico e revisão da literatura by Mary Elizabeth Kreider, David A. Lipson

    Published 2004-09-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Realização de broncofibroscopia(BFC) na atelectasia numa unidade de cuidados intensivos(UCI): um caso clínico e revisão da literatura

    Realização de broncofibroscopia(BFC) na atelectasia numa unidade de cuidados intensivos(UCI): um caso clínico e revisão da literatura by Mary Elizabeth Kreider, David A. Lipson

    Published 2003-05-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Potentiostatically Poised Electrodes Mimic Iron Oxide and Interact with Soil Microbial Communities to Alter the Biogeochemistry of Arctic Peat Soils

    Potentiostatically Poised Electrodes Mimic Iron Oxide and Interact with Soil Microbial Communities to Alter the Biogeochemistry of Arctic Peat Soils by Largus T. Angenent, Kimberley E. Miller, Elliot S. Friedman, David A. Lipson

    Published 2013-09-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis

    Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis by Ian Naya, Lee Tombs, David A. Lipson, Isabelle Boucot, Chris Compton

    Published 2019-03-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study

    Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study by John H. Riley, Chris J. Kalberg, Alison Donald, David A. Lipson, Muhammad Shoaib, Lee Tombs

    Published 2018-01-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study

    Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a r... by Peter R. Bremner, Ruby Birk, Noushin Brealey, Afisi S. Ismaila, Chang-Qing Zhu, David A. Lipson

    Published 2018-01-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Metagenomic insights into anaerobic metabolism along an Arctic peat soil profile.

    Metagenomic insights into anaerobic metabolism along an Arctic peat soil profile. by David A Lipson, John Matthew Haggerty, Archana Srinivas, Theodore K Raab, Shashank Sathe, Elizabeth A Dinsdale

    Published 2013-01-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Measuring disease activity in COPD: is clinically important deterioration the answer?

    Measuring disease activity in COPD: is clinically important deterioration the answer? by Dave Singh, Gerard J. Criner, Ian Naya, Paul W. Jones, Lee Tombs, David A. Lipson, MeiLan K. Han

    Published 2020-06-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?

    Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer? by Dave Singh, Gerard J. Criner, Ian Naya, Paul W. Jones, Lee Tombs, David A. Lipson, MeiLan K. Han

    Published 2021-11-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Dynamics of Fungal and Bacterial Biomass Carbon in Natural Ecosystems: Site‐Level Applications of the CLM‐Microbe Model

    Dynamics of Fungal and Bacterial Biomass Carbon in Natural Ecosystems: Site‐Level Applications of the CLM‐Microbe Model by Liyuan He, David A. Lipson, Jorge L. Mazza Rodrigues, Melanie Mayes, Robert G. Björk, Bruno Glaser, Peter Thornton, Xiaofeng Xu

    Published 2021-02-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Preventing clinically important deterioration with single-inhaler triple therapy in COPD

    Preventing clinically important deterioration with single-inhaler triple therapy in COPD by Ian Naya, Chris Compton, Afisi S. Ismaila, Ruby Birk, Noushin Brealey, Maggie Tabberer, Chang-Qing Zhu, David A. Lipson, Gerard Criner

    Published 2018-10-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Molecular Mirror Technology Facilitates High-Throughput, Accurate SARS-CoV-2 Testing

    Molecular Mirror Technology Facilitates High-Throughput, Accurate SARS-CoV-2 Testing by Susan Realegeno, Sara Hash, Charlene Wong, Roland Liu, Jovan Shepherd, Robert T. Schooley, David A. Lipson, Frederick Fung, Suresh Menon, David T. Pride

    Published 2021-09-01
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    Thermokarst landscape exhibits large nitrous oxide emissions in Alaska’s coastal polygonal tundra

    Thermokarst landscape exhibits large nitrous oxide emissions in Alaska’s coastal polygonal tundra by Josh Hashemi, David A. Lipson, Kyle A. Arndt, Scott J. Davidson, Aram Kalhori, Kyle Lunneberg, Lona van Delden, Walter C. Oechel, Donatella Zona

    Published 2024-08-01
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses

    Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses by David M.G. Halpin, Ruby Birk, Noushin Brealey, Gerard J. Criner, Mark T. Dransfield, Emma Hilton, David A. Lomas, Chang-Qing Zhu, David A. Lipson

    Published 2018-05-01
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial

    Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial by Claus F. Vogelmeier, Paul W. Jones, Edward M. Kerwin, Isabelle H. Boucot, François Maltais, Lee Tombs, Chris Compton, David A. Lipson, Leif H. Bjermer

    Published 2021-10-01
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    Early and sustained symptom improvement with umeclidinium/vilanterol monotherapy in COPD: a analysis of the EMAX randomised controlled trial

    Early and sustained symptom improvement with umeclidinium/vilanterol monotherapy in COPD: a analysis of the EMAX randomised controlled trial by Edward M Kerwin, Isabelle H Boucot, Claus F Vogelmeier, Francois Maltais, Ian P Naya, Lee Tombs, Paul W Jones, David A Lipson, Tom Keeley, Leif Bjermer

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT

    Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT by José M. Marín, Luis Mateos, Juan Roldán, José M. Echave-Sustaeta, Sergi Pascual-Guardia, Maria V. Pardo, Beatriz Velasco, C. Elaine Jones, Sally Kilbride, David A. Lipson

    Published 2020-10-01
    Get full text
    Article
    Save to List
    Saved in:
  19. 19
    Impact of baseline COPD symptom severity on the benefit from dual mono-bronchodilators: an analysis of the EMAX randomised controlled trial

    Impact of baseline COPD symptom severity on the benefit from dual mono-bronchodilators: an analysis of the EMAX randomised controlled trial by Claus F. Vogelmeier, Edward M. Kerwin, Leif H. Bjermer, Lee Tombs, Paul W. Jones, Isabelle H. Boucot, Ian P. Naya, David A. Lipson, Chris Compton, Neil Barnes, François Maltais

    Published 2020-11-01
    Get full text
    Article
    Save to List
    Saved in:
  20. 20
    Intensified Positive Arctic–Methane Feedback under IPCC Climate Scenarios in the 21st Century

    Intensified Positive Arctic–Methane Feedback under IPCC Climate Scenarios in the 21st Century by Yihui Wang, Liyuan He, Jianzhao Liu, Kyle A. Arndt, Jorge L. Mazza Rodrigues, Donatella Zona, David A. Lipson, Walter C. Oechel, Daniel M. Ricciuto, Stan D. Wullschleger, Xiaofeng Xu

    Published 2024-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: